126 related articles for article (PubMed ID: 37679051)
1. TSC2 inactivation, low mutation burden and high macrophage infiltration characterise hepatic angiomyolipomas.
Giannikou K; Klonowska K; Tsuji J; Wu S; Zhu Z; Probst CK; Kao KZ; Wu CL; Rodig S; Marino-Enriquez A; Zen Y; Schaefer IM; Kwiatkowski DJ
Histopathology; 2023 Oct; 83(4):569-581. PubMed ID: 37679051
[TBL] [Abstract][Full Text] [Related]
2. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.
Giannikou K; Malinowska IA; Pugh TJ; Yan R; Tseng YY; Oh C; Kim J; Tyburczy ME; Chekaluk Y; Liu Y; Alesi N; Finlay GA; Wu CL; Signoretti S; Meyerson M; Getz G; Boehm JS; Henske EP; Kwiatkowski DJ
PLoS Genet; 2016 Aug; 12(8):e1006242. PubMed ID: 27494029
[TBL] [Abstract][Full Text] [Related]
3. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma.
Pan CC; Chung MY; Ng KF; Liu CY; Wang JS; Chai CY; Huang SH; Chen PC; Ho DM
J Pathol; 2008 Feb; 214(3):387-93. PubMed ID: 18085521
[TBL] [Abstract][Full Text] [Related]
4. Renal angiomyolipoma (AML) harboring a missense mutation of
Idogawa M; Hida T; Tanaka T; Ohira N; Tange S; Sasaki Y; Uhara H; Masumori N; Tokino T; Natori H
Cancer Biol Ther; 2020 Apr; 21(4):315-319. PubMed ID: 31847710
[TBL] [Abstract][Full Text] [Related]
5. Biallelic TSC gene inactivation in tuberous sclerosis complex.
Crino PB; Aronica E; Baltuch G; Nathanson KL
Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
7. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
[TBL] [Abstract][Full Text] [Related]
8. Germline mutation of TSC1 or TSC2 gene in Chinese patients with bilateral renal angiomyolipomas and mutation spectrum of Chinese TSC patients.
Jiangyi W; Gang G; Guohai S; Dingwei Y
Aging (Albany NY); 2020 Jan; 12(1):756-766. PubMed ID: 31927531
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
[TBL] [Abstract][Full Text] [Related]
10. The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex.
Yang HM; Choi HJ; Hong DP; Joo SY; Lee NE; Song JY; Choi YL; Lee J; Choi D; Kim B; Park HJ; Park JB; Kim SJ
Exp Mol Pathol; 2014 Dec; 97(3):440-4. PubMed ID: 25281918
[TBL] [Abstract][Full Text] [Related]
11. Low-level mosaicism in tuberous sclerosis complex in four unrelated patients: Comparison of clinical characteristics and diagnostic pathways.
Manzanilla-Romero HH; Weis D; Schnaiter S; Rudnik-Schöneborn S
Am J Med Genet A; 2021 Dec; 185(12):3851-3858. PubMed ID: 34328706
[TBL] [Abstract][Full Text] [Related]
12. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype correlation of patients with tuberous sclerosis complex-associated renal angiomyolipoma: a descriptive study.
Li S; Zhang Y; Wang Z; Yang Y; Gao W; Li D; Wei J
Hum Pathol; 2018 Dec; 82():61-67. PubMed ID: 30036593
[TBL] [Abstract][Full Text] [Related]
14. The association of neurodevelopmental abnormalities, congenital heart and renal defects in a tuberous sclerosis complex patient cohort.
Robinson J; Uzun O; Loh NR; Harris IR; Woolley TE; Harwood AJ; Gardner JF; Syed YA
BMC Med; 2022 Apr; 20(1):123. PubMed ID: 35440050
[TBL] [Abstract][Full Text] [Related]
15. Dissecting TSC2-mutated renal and hepatic angiomyolipomas in an individual with ARID1B-associated intellectual disability.
Popp B; Agaimy A; Kraus C; Knaup KX; Ekici AB; Uebe S; Reis A; Wiesener M; Zweier C
BMC Cancer; 2019 May; 19(1):435. PubMed ID: 31077186
[TBL] [Abstract][Full Text] [Related]
16. Detection of TSC1/TSC2 mosaic variants in patients with cardiac rhabdomyoma and tuberous sclerosis complex by hybrid-capture next-generation sequencing.
Wang S; Sun H; Wang J; Gu X; Han L; Wu Y; Yan H; Han L; Zhang H; He Y
Mol Genet Genomic Med; 2021 Oct; 9(10):e1802. PubMed ID: 34480426
[TBL] [Abstract][Full Text] [Related]
17. Angiomyolipoma have common mutations in TSC2 but no other common genetic events.
Qin W; Bajaj V; Malinowska I; Lu X; MacConaill L; Wu CL; Kwiatkowski DJ
PLoS One; 2011; 6(9):e24919. PubMed ID: 21949787
[TBL] [Abstract][Full Text] [Related]
18. Sporadic facial angiofibroma and sporadic angiomyolipoma mimicking tuberous sclerosis complex.
Klonowska K; Thiele EA; Grevelink JM; Thorner AR; Kwiatkowski DJ
J Med Genet; 2022 Sep; 59(9):920-923. PubMed ID: 34635572
[TBL] [Abstract][Full Text] [Related]
19. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
Smolarek TA; Wessner LL; McCormack FX; Mylet JC; Menon AG; Henske EP
Am J Hum Genet; 1998 Apr; 62(4):810-5. PubMed ID: 9529362
[TBL] [Abstract][Full Text] [Related]
20. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
